Business Context and Reporting Period
This Form 8-K Current Report was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on April 1, 2014, covering events that occurred on March 26, 2014. The filing details significant changes to the Company's Board of Directors, including resignations, new appointments, and the restructuring of board committees.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes Versus Prior Period
- Board Resignations: Hojabr Alimi (Company Founder) and Richard Conley resigned from the Board of Directors and all committee appointments effective March 26, 2014.
- New Director Appointment: Sharon Barbari was appointed as a director, Chairperson of the Audit Committee, and member of the Nominating and Corporate Governance Committee.
- Lead Independent Director: Jerry McLaughlin was appointed as the Lead Independent Director.
- Committee Restructuring: The Board reorganized into three committees: Audit, Compensation, and Nominating and Corporate Governance, with new membership assignments.
- Compensation Program: A new Non-Employee Director Compensation Program was adopted, establishing specific cash retainers and equity grant structures.
Guidance, Outlook, and Management Commentary
Management stated that the creation of a Lead Independent Director position was determined to best support the Company's needs and assist the Board in monitoring management to create long-term value. The filing includes no financial guidance, risk factors, or discussion of contingencies beyond the standard indemnification agreements entered into with the new director.
Director Compensation Details
| Role | Annual Cash Retainer |
|---|---|
| Board Member | $32,500 |
| Lead Independent Director | $15,000 |
| Audit Committee Chair | $10,000 |
| Compensation Committee Chair | $5,000 |
| Nominating & Governance Committee Chair | $5,000 |
| Audit Committee Member (Non-Chair) | $7,500 |
| Compensation Committee Member (Non-Chair) | $2,000 |
| Nominating & Governance Member (Non-Chair) | $2,000 |
Equity Grants: New directors receive an initial option to purchase 50,000 shares (vesting over 3 years). Annual grants of 15,000 shares are provided to non-employee directors (vesting over 1 year). Audit Committee fees must be paid in cash; other fees may be elected as cash, options, or stock.
Important Facts for Investor Verification
- Verify the departure of the Company's founder, Hojabr Alimi, and the strategic implications of his resignation.
- Confirm the background and qualifications of the new director, Sharon Barbari, particularly her experience in biopharmaceutical finance.
- Review the total potential dilution from the new director equity compensation program (50,000 initial shares + 15,000 annual shares per non-employee director).
- Check subsequent filings to ensure the new committee structure and Lead Independent Director role are functioning as intended.